The client, a large pharmaceutical company, wanted to understand the implications of the Office of Fair Trading decision in respect of hospital vs. community politiques de prix of Morphine Continus® in the UK for its own politiques de prix strategies.
Translucency reviewing the case and, using its detailed existing knowledge of pharmaceutical politiques de prix in the UK, and incorporating information our client had given about its own current approach to politiques de prix, prepared a full briefing about the issues.
Translucency’s report related the findings to the likely effects on the client’s approach to politiques de prix in the UK.
The client recommendations have informed the client’s decisions on relative politiques de prix of products in the hospital and in the community.